SCHEMBL676787

SCHEMBL676787

CCCCC(N)c1cnc2[nH]c3ccc(-c4cccc([N+](=O)[O-])c4)cc3c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.41
ALK Q9UM73 1/20 0.39
RAF1 P04049 1/20 0.39
BRAF P15056 1/20 0.39
IDO1 P14902 1/20 0.37
PTK6 Q13882 3/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
ERBB2 P04626 2/20 0.36
KMO O15229 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
PIK3CA P42336 1/20 0.35
PIK3CG P48736 1/20 0.35
GABRA1 P14867 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677177 0.85 GABRA1 (0.37) ALKIDO1MMP2MMP9MMP8
SCHEMBL674779 0.83 PGR (0.42) PGRALKADORA2AADORA1DRD2
SCHEMBL3724337 0.82 PGR (0.44) PGRALKRAF1BRAFIDO1
SCHEMBL675723 0.79 CCNB2 (0.40) ALK
SCHEMBL3724572 0.78 ALDH1A1 (0.40) PGRALKRAF1BRAFIDO1
SCHEMBL3724571 0.78 ALDH1A1 (0.40) PGRALKRAF1BRAFIDO1
SCHEMBL675581 0.77 GABRA1 (0.42) IDO1MMP2MMP9MMP8MMP13
SCHEMBL676788 0.76 PGR (0.43) PGRALKRAF1BRAFIDO1
SCHEMBL676789 0.74 PGR (0.40) PGRADORA2AADORA1DRD2HTR2A
SCHEMBL674781 0.74 TLR8 (0.42) PGRADORA2AADORA1DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 PGR 2572/4885ALK 1/4885RAF1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.